key: cord-0972678-9m9tkj3p
authors: Jerusalem, G.; Onesti, C. E.; Generali, D. G.; Harbeck, N.; Wildiers, H.; Curigliano, G.; Campone, M.; Tjan-Heijnen, V.; Martin, M.; Cristofanilli, M.; Pusztai, L.; Bartsch, R.; Peeters, M.; Berchem, G.; Tagliamento, M.; Cortés, J.; Ruhstaller, T.; Ciruelos, E. M.; Rottey, S.; Rugo, H. S.
title: Expected medium and long term impact of the COVID-19 outbreak in oncology
date: 2020-09-30
journal: Annals of Oncology
DOI: 10.1016/j.annonc.2020.08.2317
sha: e62ea06d4bb53c8271b0dcbc94a927ee1bcc14a1
doc_id: 972678
cord_uid: 9m9tkj3p

nan

Background: The ongoing SARS-CoV-2 pandemic and ensuing coronavirus disease is challenging cancer care and services worldwide.

Methods: A 95 items survey was distributed worldwide by 20 oncologists from 10 of the most affected countries in order to evaluate the impact on organization of oncological care.

Results: 109 representatives from oncology centers in 18 countries (62.4% academic hospitals) filled out the survey (June 17 e July 14, 2020). A swab or gargle test is systematically performed before day care unit or overnight stay admissions in 27.5% and 58.7% of the centers, respectively. A local registry (64.2%) and systematic tracing (77.1%) of infected patients was organized in many centers. Treatment modalities mostly affected by the pandemic (cancellation/delay) were surgery (44.1%) and chemotherapy (25.7%). Earlier cessation of palliative treatment was observed in 32.1% of centers, and 64.2 % of participants agree that under-treatment is a major concern. At the pandemic peak, teleconsultations were performed for follow-up (94.5%), for oral therapy (92.7%), but also for patients receiving immunotherapy (57.8%) or chemotherapy (55%). Approximately 82% of participants estimate that they will continue to use telemedicine. Most participants reported more frequent use of virtual tumor boards (82%) and oncological team meetings (92%), but 45% disagree that virtual meetings are an acceptable alternative to live international meetings. Although 60.9% report reduced clinical activity during the pandemic peak, only 28.4% had an increased scientific activity. Only 18% of participants estimate that their wellbeing will not recover to previous levels by the end of the year; 63% indicate easily accessible psychological support for caregivers, but only 10% used or planned to use it. All clinical trial activities are or will soon be reactivated in 72.5% of the centers. Major study protocol violations/deviations were observed in 27.5% and significant reductions of clinical trial activities are expected by 37% of centers this year.

Conclusions: COVID-19 has a major impact on organization of patient care, well-being of caregivers, continued medical education and clinical trial activities in oncology.

LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study A

UO Patologia Mammaria e Ricerca Traslazionale -Breast Unit

Methods: This is a multicenter, observational, prospective study that included patients and oncology healthcare workers (HCWs) with SARS-CoV-2 infection confirmed by RT-PCR or clinical/radiological suspicious of infection as well as patients with cancer who are considered at high risk for infection. All subjects were tested with the 2019-nCoV IgG/IgM Rapid Test Cassett for the fast detection of IgG and IgM antibodies against SARS-CoV-2. The aim of the study was to evaluate anti-SARS-CoV-2 seroconversion rates by qualitative assay

Eighty-six subjects (51.8%) had confirmed SARS-CoV-2 diagnosis by RT-PCR testing on nasopharyngeal swab specimen, while forty-nine (29.5%) had a clinical suspicious of COVID-19 in absence of RT-PCR confirmation. In patients with RT-PCR-confirmed SARS-CoV-2 infection, 62 (83.8%) were IgG-positive. Neither differences in terms of IgG positivity (87.9% vs 80.5%; P¼0.39) nor in median time from COVID-19 diagnosis to IgG detection (23.0 vs 28.0 days; P¼0.21) were found between patients with cancer and HCWs. Conclusions: Our data show that SARS-CoV-2-specific IgG antibody response is not different between cancer patients and healthy subjects. Qualitative rapid test for antibody detection represents an useful support to RNA RT-PCR testing for the diagnosis of COVID-19 in high-risk populations, including patients with cancer. Legal entity responsible for the study: Istituto Europeo di Oncologia IRCCS. Funding: This work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds

Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy: Mylan, Daichii Sankyo; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly, Pfizer, Merck, Foundation Medicine, Samsung, Celltrion; Advisory/ Consultancy, Speaker Bureau/Expert testimony: Seattle Genetics, Nanostring; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: Novartis, BMS; Honoraria (self): Ellipsis. All other authors have declared no conflicts of interest

Legal entity responsible for the study: The authors. AbbVie; Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: AstraZeneca; Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Blue Print Medicines; Advisory/Consultancy, Advisory role or speaker's bureau: Boehringer Ingelheim; Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Bristol-Myers Squibb; Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: GSK; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Eli Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Guardant Health; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Janssen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Medscape; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Merck KGaA; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Merck Sharp and Dohme; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: prIME Oncology; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Samsung; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Springer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Advisory role or Speaker's bureau: Takeda Travel/Accommodation/Expenses, CME presentation (travel funding): Fishawack facilitate LTD; Travel/Accommodation/Expenses, CME presentation (travel funding): Medscape; Travel/Accommodation/Expenses, CME presentation (travel funding): Onclive/intellisphere LLC; Travel/Accommodation/Expenses, CME presentation (travel funding): Philips Gillmore Oncology 2018; Travel/Accommodation/Expenses, CME presentation (travel funding): Physician education resource, LLC/MJH; Travel/Accommodation/Expenses, CME presentation (travel funding): Potomac center for medical education; Travel/Accommodation/Expenses, CME presentation (travel funding): Prime Oncology LLC (2018); Travel/Accommodation/ Expenses, CME presentation (travel funding): Primo (2018); Travel/Accommodation/Expenses, CME presentation (travel funding): Research to practice; Travel/Accommodation/Expenses, CME presentation (travel funding): UpToDate; Travel/Accommodation/Expenses, CME presentation (travel funding): WebMdHealth; Honoraria (self), Research grant/Funding (institution), honoraria, research funding to: Novartis; Travel/Accommodation/Expenses, International professional society: RGCON-Rajiv gand conference; Travel/Accommodation/Expenses, International professional society: JLCSjapanese lung cancer society; Travel/Accommodation/Expenses, International professional society: KSMO -korean society of medical oncology; Full/Part-time employment, professor of medicine: Stanford university; Travel/Accommodation/Expenses, Scientific advisory committe -travel: ITMIG; Research grant/Funding (institution), research funding to institution: ACEA biosciences. M.C.